中国新药杂志

非酒精性脂肪肝病中线粒体功能紊乱及其治疗策略

PDF下载

雷蕾 , 彭宗根

中国新药杂志 | 重大新药创制专项巡礼 2021,30(24): 2268-2275

收起

中国新药杂志 |重大新药创制专项巡礼 2021 , 30 (24) : 2268 -2275

非酒精性脂肪肝病中线粒体功能紊乱及其治疗策略

全屏

[Author(id=1322127432191168870, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=leilei010017@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322127432287637864, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, authorId=1322127432191168870, language=EN, stringName=Lei LEI, firstName=Lei, middleName=null, lastName=LEI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322127432375718249, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, authorId=1322127432191168870, language=CN, stringName=雷蕾, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医学科学院北京协和医学院医药生物技术研究所，北京　100050, bio={"content":"

雷蕾，女，博士研究生，主要从事抗肝炎药物分子药理学研究。E-mail：leilei010017@163.com。

"}, bioImg=null, bioContent=

雷蕾，女，博士研究生，主要从事抗肝炎药物分子药理学研究。E-mail：leilei010017@163.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322127432094699874, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, xref=null, ext=[AuthorCompanyExt(id=1322127432107282787, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, companyId=1322127432094699874, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1322127432115671396, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, companyId=1322127432094699874, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医学科学院北京协和医学院医药生物技术研究所，北京　100050)])]), Author(id=1322127432459604331, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=pumcpzg@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322127432543490413, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, authorId=1322127432459604331, language=EN, stringName=Zong-gen PENG, firstName=Zong-gen, middleName=null, lastName=PENG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322127432606404974, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, authorId=1322127432459604331, language=CN, stringName=彭宗根, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医学科学院北京协和医学院医药生物技术研究所，北京　100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322127432094699874, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, xref=null, ext=[AuthorCompanyExt(id=1322127432107282787, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, companyId=1322127432094699874, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China), AuthorCompanyExt(id=1322127432115671396, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127431440388447, companyId=1322127432094699874, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医学科学院北京协和医学院医药生物技术研究所，北京　100050)])])]

雷蕾, 彭宗根

作者信息

中国医学科学院北京协和医学院医药生物技术研究所，北京　100050

通讯作者:

彭宗根，男，研究员，博士生导师，主要从事抗肝炎药物分子药理学研究。联系电话：（010）63166129，E-mail：pumcpzg@126.com。

作者简介:

雷蕾，女，博士研究生，主要从事抗肝炎药物分子药理学研究。E-mail：leilei010017@163.com。

Mitochondrial dysfunction in non-alcoholic fatty liver disease and its therapeutic strategies

Lei LEI, Zong-gen PENG

Affiliations

Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China

出版时间: 2021-12-30

文章导航

摘要

收起

非酒精性脂肪肝病（NAFLD）是一种与代谢紊乱密切相关的肝脏疾病，最主要的特征之一是肝脏线粒体功能紊乱，可导致单纯的肝脂肪变性或发展为脂肪性肝炎，甚至出现肝纤维化，最终可能导致肝硬化和肝癌发生。但目前临床上尚无针对NAFLD病因的特效治疗药物。近年来的研究发现线粒体功能紊乱与其超微结构损伤、线粒体DNA缺失、活性氧过度产生、异常的脂肪酸氧化、线粒体自噬、凋亡以及信号转导等相关。本文综述了线粒体功能紊乱在NAFLD进展中的表现、作用及其发生机制，并基于对线粒体功能紊乱的理解进一步探讨NAFLD的治疗策略，为研发防治NAFLD的创新药物提供新思路。

关键词

非酒精性脂肪肝 / 线粒体 / 功能紊乱 / 治疗药物

Abstract

收起

Non-alcoholic fatty liver disease (NAFLD) is a liver disease closely related to metabolic syndrome. Hepatic mitochondrial dysfunction, as one of the most important features of NAFLD, leads to simple liver steatosis or progresses to steatohepatitis, and even liver fibrosis, which may eventually induce cirrhosis and hepatocellular carcinoma. However, there is no specific drug for the treatment of NAFLD in clinic. Recent studies found that mitochondrial dysfunction is related to ultrastructural damage, mitochondrial DNA depletion, excessive production of reactive oxygen species, and abnormities of fatty acid oxidation, mitochondrial autophagy, apoptosis, signal transduction. This article reviewed the performance, role, and mechanism of mitochondrial dysfunction in the progression of NAFLD and discussed the therapeutic strategies of NAFLD based on the understanding of mitochondrial dysfunction in NAFLD, providing new ideas for the development of innovative drugs for the prevention and treatment of NAFLD.

Key words

non-alcoholic fatty liver / mitochondria / dysfunction / therapeutic drug

引用本文

雷蕾, 彭宗根. 非酒精性脂肪肝病中线粒体功能紊乱及其治疗策略. 中国新药杂志, 2021 , 30 (24) : 2268 -2275 .

Lei LEI, Zong-gen PENG. Mitochondrial dysfunction in non-alcoholic fatty liver disease and its therapeutic strategies[J]. Chinese Journal of New Drugs, 2021 , 30 (24) : 2268 -2275 .

基金

收起

国家重大新药创制科技重大专项资助项目(2018ZX09711001-003-010)
中国医学科学院医学与健康科技创新工程课题资助项目(2017-I2M-3-012)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

YOUNOSSI ZM. Non-alcoholic fatty liver disease-A global public health perspective[J]. J Hepatol, 2019, 70(3): 531-544.

[2]

YOUNOSSI ZM, MARCHESINI G, PINTO-CORTEZ H, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation[J]. Transplantation, 2019, 103(1): 22-27.

[3]

BYRNE CD, TARGHER G. What's new in NAFLD pathogenesis, biomarkers and treatment?[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(2): 70-71.

[4]

KONERMAN MA, JONES JC, HARRISON SA. Pharmacotherapy for NASH: Current and emerging[J]. J Hepatol, 2018, 68(2): 362-375.

[5]

MANSOURI A, GATTOLLIAT CH, ASSELAH T. Mitochondrial dysfunction and signaling in chronic liver diseases[J]. Gastroenterology, 2018, 155(3): 629-647.

[6]

LONGO M, MERONI M, PAOLINI E, et al. Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?[J]. Metabolism, 2021, 117: 154708.

[7]

PLOUMI C, DASKALAKI I, TAVERNARAKIS N. Mitochondrial biogenesis and clearance: a balancing act[J]. Febs J, 2017, 284(2): 183-195.

[8]

BESSONE F, RAZORI MV, ROMA MG. Molecular pathways of nonalcoholic fatty liver disease development and progression[J]. Cell Mol Life Sci, 2019, 76(1): 99-128.

[9]

MIHM S. Danger-associated molecular patterns (DAMPs): molecular triggers for sterile inflammation in the liver[J]. Int J Mol Sci, 2018, 19(10): 3104.

[10]

KRENKEL O, TACKE F. Liver macrophages in tissue homeostasis and disease[J]. Nat Rev Immunol, 2017, 17(5): 306-321.

[11]

SCHUSTER S, CABRERA D, ARRESE M, et al. Triggering and resolution of inflammation in NASH[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 349-364.

[12]

AJITH TA. Role of mitochondria and mitochondria-targeted agents in non-alcoholic fatty liver disease[J]. Clin Exp Pharmacol Physiol, 2018, 45(5): 413-421.

[13]

AN P, WEI LL, ZHAO S, et al. Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis[J]. Nat Commun, 2020, 11(1): 2362.

[14]

ARAB JP, ARRESE M, TRAUNER M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease[J]. Annu Rev Pathol, 2018, 13: 321-350.

[15]

YAMADA T, MURATA D, ADACHI Y, et al. Mitochondrial stasis reveals p62-mediated ubiquitination in parkin-independent mitophagy and mitigates nonalcoholic fatty liver disease[J]. Cell Metab, 2018, 28(4): 588-604.

[16]

WANG L, LIU X, NIE J, et al. ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis[J]. Hepatology, 2015, 61(2): 486-496.

[17]

ZHOU T, CHANG L, LUO Y, et al. Mst1 inhibition attenuates non-alcoholic fatty liver disease via reversing Parkin-related mitophagy[J]. Redox Biol, 2019, 21: 101120.

[18]

LI R, XIN T, LI D, et al. Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: The role of the ERK-CREB pathway and Bnip3-mediated mitophagy[J]. Redox Biol, 2018, 18: 229-243.

[19]

ROTMAN Y, SANYAL AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease[J]. Gut, 2017, 66(1): 180-190.

[20]

IPSEN DH, LYKKESFELDT J, TVEDEN-NYBORG P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease[J]. Cell Mol Life Sci, 2018, 75(18): 3313-3327.

[21]

HERZIG S, SHAW RJ. AMPK: guardian of metabolism and mitochondrial homeostasis[J]. Nat Rev Mol Cell Biol, 2018, 19(2): 121-135.

[22]

DAY EA, FORD RJ, STEINBERG GR. AMPK as a therapeutic target for treating metabolic diseases[J]. Trends Endocrinol Metab, 2017, 28(8): 545-560.

[23]

NAGAO H, NISHIZAWA H, BAMBA T, et al. Increased dynamics of tricarboxylic acid cycle and glutamate synthesis in obese adipose tissue: in vivo metabolic turnover analysis[J]. J Biol Chem, 2017, 292(11): 4469-4483.

[24]

FRIEDMAN SL, NEUSCHWANDER-TETRI BA, RINELLA M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922.

[25]

FOURET G, TOLIKA E, LECOMTE J, et al. The mitochondrial-targeted antioxidant, MitoQ, increases liver mitochondrial cardiolipin content in obesogenic diet-fed rats[J]. Biochim Biophys Acta, 2015, 1847(10): 1025-1035.

[26]

GUTIERREZ-MARISCAL FM, ARENAS-DE LARRIVA AP, LIMIA-PEREZ L, et al. Coenzyme Q10 supplementation for the reduction of oxidative stress: clinical implications in the treatment of chronic diseases[J]. Int J Mol Sci, 2020, 21(21): 7870.

[27]

CHEN K, CHEN X, XUE H, et al. Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway[J]. Food Funct, 2019, 10(2): 814-823.

[28]

SUNNY NE, BRIL F, CUSI K. Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies[J]. Trends Endocrinol Metab, 2017, 28(4): 250-260.

[29]

FERRAMOSCA A, DI GIACOMO M, ZARA V. Antioxidant dietary approach in treatment of fatty liver: New insights and updates[J]. World J Gastroenterol, 2017, 23(23): 4146-4157.

[30]

YI YS. Regulatory roles of flavonoids on inflammasome activation during inflammatory responses[J]. Mol Nutr Food Res, 2018, 62(13): e1800147.

[31]

谢鹏超, 邱利焱. 纳米载体在非酒精性脂肪肝药物治疗中的研究进展[J]. 中国现代应用药学, 2021, 38(13): 1610-1617.

2021年第30卷第24期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-12-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-10-08

基金

国家重大新药创制科技重大专项资助项目(2018ZX09711001-003-010)

中国医学科学院医学与健康科技创新工程课题资助项目(2017-I2M-3-012)

作者信息

中国医学科学院北京协和医学院医药生物技术研究所，北京　100050

通讯作者:

彭宗根，男，研究员，博士生导师，主要从事抗肝炎药物分子药理学研究。联系电话：（010）63166129，E-mail：pumcpzg@126.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322127431440388447

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT